ONA Therapeutics Strengthens Scientific Leadership Team

  • Industry veteran in oncology antibody discovery & development Dr Haijun Sun appointed Chief Scientific Officer

  • Expansion of the Scientific Advisory Board with appointments of leading experts in preclinical, translational and clinical drug development

Barcelona, Spain, 21 October 2021: ONA Therapeutics (“ONA”), which is focused on the discovery and development of therapeutic biologics targeting lipid metabolism in order to treat advanced cancer, announces today the appointment of Dr Haijun Sun as Chief Scientific Officer (CSO) and several appointments to its Scientific Advisory Board (SAB).

Read more…